[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 15, 2015

Alternating Electric Fields for the Treatment of Glioblastoma

Author Affiliations
  • 1Department of Neurosurgery, Duke University, Durham, North Carolina
JAMA. 2015;314(23):2511-2513. doi:10.1001/jama.2015.16701

Glioblastoma is the most common malignant tumor of the central nervous system,1 and one of the most difficult cancers to treat. Standard therapy includes maximal surgical resection, high-dose external-beam radiation therapy, and regional or systemic chemotherapy. Still, 5-year survival rates are only 5%.1 Current therapies lack specificity, fail to address tumor heterogeneity, or are limited because of an inability to penetrate the blood-brain barrier. Because conventional strategies lack success, investigational approaches,26 with varying degrees of supportive evidence, are often used. Historically, advances in this field have been separated by decades of failure. Life expectancy for patients with glioblastoma has changed little during the past decade, and median survival remains at less than 15 months.7

First Page Preview View Large
First page PDF preview
First page PDF preview
×